500 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Investor Presentation
Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Securities Purchase Agreement
Jeff Sacher Appointed Treasurer and Interim CFO at Foghorn Therapeutics
Provides Third Quarter 2025 Financial and Corporate Update
Reg. FD
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement